Hepatocelular Carcinoma with Tumor Thrombus in Portal Vein:Finding in Ultrasonography,Computed Tomography,Angiography and Chemoembolization

ＨｅｐａｔｏｃｅｌｕｌａｒＣａｒｃｉｎｏｍａｗｉｔｈＴｕｍｏｒＴｈｒｏｍｂｕｓｉｎＰｏｒｔａｌＶｅｉｎ：ＦｉｎｄｉｎｇｉｎＵｌｔｒａｓｏｎｏｇｒａｐｈｙ，ＣｏｍｐｕｔｅｄＴｏｍｏｇｒａｐｈｙ，ＡｎｇｉｏｇｒａｐｈｙａｎｄＣｈｅｍｏｅｍｂｏｌｉｚａｔｉ...     

金珠滴眼液治疗慢性结膜炎的临床研究

目的　探讨金珠滴眼液治疗慢性结膜炎的疗效。方法　将慢性结膜炎患者 36例 6 8眼随机分为2组 ,每组 34眼 ,实验组用 7.8%金珠滴眼液点眼治疗 ,对照组用 0 .2 5 %氯霉素点眼治疗。结果　金珠滴眼液1、2、4周疗效的综合分值判定均与对照组有显著差异 (P <0 .0 5 ) ,且无局部刺激性。结论　金珠滴眼液对慢性结膜炎有明显的治疗作用 ,可望为临床常见多发的慢性结膜炎患者消除或缓解症状     

Embolization of dural arteriovenous fistulas draining into the transverse or sigmoid sinus

The results of embolisation of dural arteriovenous fistulas draining into the transverse or sigmoid sinus were evaluated in 20 patients. Tinnitus was the main symptom in all patients although one also suffered from vertigo and sudden deafness. Nine patients were treated with PVA (polyvinylalcohol) alone and 11 with combined PVA and bucrylate (isobutyl-2-cyanoacrylate) in 1–9 procedures. Recurrence of symptoms, requiring repeated procedures was common but at subsequent clinical follow up 10 patients had no tinnitus, 5 were improved and only 5 experienced no change. Complications occured in six patients: four had transient neurological symptoms and one of these also developed a necrotic wound which later healed. One patient suffered from a cranial nerve palsy and one had an intracranial haemorrhage after a transvenous embolisation. This last patient recovered completely. The best clinical results were achieved in small fistulas and fistulas treated with combined bucrylate and PVA.     

垂体后叶素和硝酸甘油联合治疗食管静脉曲张破裂大出血

３０例肝硬化食管静脉曲张破裂大出血患者，用垂体后叶素０．２～０．４Ｕ／ｍｉｎ连续静脉滴注和硝酸甘油含服联合治疗。结果表明，近期止血有效申达８０％，死亡率１０％；无一例出现严重心绞痛和心电图异常。     

1999～2001年全国治疗药物监测室间质评结果

目的:通过开展室间质量评价活动提高临床实验室的检验结果质量。方法:每年向参加治疗药物监测(TDM)室间质量评价活动的单位发放质控品10个批号,测定项目包括茶碱、地高辛、苯妥英、苯巴比妥、卡马西平和环孢菌素A,实验室用常规方法测定并回报测定结果,经计算机软件对全部结果进行统计分析。结果:2001年参加TDM室间质评的实验室数为48家,测定结果的平均及格率分别为茶碱94.2％、地高辛82.6％、苯妥英83.8％、苯巴比妥88.4％、卡马西平94.2和环孢菌素A92.4％。1999～2001年全国TDM室间质评的年平均及格率分别为78.7％、84.7％和89.3％。不同测定方法的精密度分别为茶碱4.4％～14.2％、地高辛11.5％～21.9％、苯妥英8.5％～29.5％、苯巴比妥8.2％～13.9％、卡马西平10.8％～12.6％和环孢菌素A15.5％～16.6％。结论:多数参加TDM室间质评实验室的测定结果有较好的一致性,及格率逐年上升,但参加TDM室间质评的实验室数占开展TDM的实验室总数的比例较低,在不同的测定方法间还存在较大的差异。     

Characterization of Aerosols of Human Recombinant Deoxyribonuclease I (rhDNase) Generated by Jet Nebulizers

Recombinant human deoxyribonuclease I (rhDNase) is a new therapeutic agent developed to improve clearance of purulent sputum from the human airways. It is delivered by inhalation. Four jet nebulizers, T Up-Draft II (Hudson), Customized Respirgard II (Marquest), Acorn II (Marquest), and Airlife Misty (Baxter), were evaluated in vitro for their ability to deliver aerosols of rhDNase. The aerosols were generated from 2.5-mL aqueous solutions of rhDNase, at concentrations of either 1 or 4 mg/mL. In all experiments, the Pulmo-Aide Compressor (De Vilbiss) was used to supply the air to the nebulizers. Between 20 and 28% of the rhDNase dose initially placed in the nebulizers was delivered to the mouthpiece in the respirable range (1-6 µm). Evaluation of the rhDNase following nebulization in all four devices indicated that there was no loss in enzymatic activity and no increase in aggregation. Circular dichroism spectrophotometry indicated there was no change in either the secondary or the tertiary structure in rhDNase following nebulization. These results show that all four nebulizers are essentially equivalent in their ability to deliver respirable doses of rhDNase in an intact, fully active form. Changing the concentration of the solution in the nebulizer from 4 to 1 mg/mL rhDNase leads to a proportional reduction in the respirable dose delivered to the mouthpiece.     

钻孔闭式引流和YL-1型穿刺针引流治疗慢性硬膜下血肿的疗效观察

目的比较钻孔闭式引流和YL—1型穿刺针引流在治疗慢性硬膜下血肿(CSDH)的疗效。方法回顾分析了我院收治的62例CSDH病人,45例行钻孔闭式引流术(甲组),17例行YL—1型穿刺针引流术(乙组),比较两组治疗效果。结果甲组复发率为6.5％,并发症率为4.1％,乙组复发率为27.7％,并发症率为22.2％。结论钻孔闭式引流较YL-1型穿刺针引流可明显减少CSDH复发率和并发症发生率。     

经导管肝动脉栓塞化疗术(TACE)对肝癌细胞凋亡相关蛋白fas,bax和bcl-xl表达影响的相关研究

目的　探讨经导管肝动脉栓塞化疗术 (TACE)对肝细胞癌 (HCC)细胞凋亡相关蛋白fas ,bax和bcl -xl表达的影响 ,评价TACE对肝细胞癌的疗效。方法　经病理证实的肝细胞癌 63例 ,包括单纯手术组 42例 ,TACE组 2 1例 (为TACE治疗后 2次有手术机会而行切除者 ) ;采用免疫组织化学SP法检测标本fas ,bax和bcl -xl的表达情况 ,将 2组结果进行对照分析。结果　TACE组fas表达阳性率为 47.62 % ( 10 / 2 1) ,单纯手术组fas表达阳性率为 2 1.43 % ( 9/ 42 ) ,二者之间有显著性差异 (Ρ <0 .0 5 ) ,TACE组明显高于单纯手术组 ;TACE组bcl -xl表达阳性率为 2 3 .81% ( 5 / 2 1) ,单纯手术组阳性率为 5 4.76% ( 2 3 / 42 ) ,二者之间亦有显著性差异 (Ρ <0 .0 5 ) ,TACE组明显低于单纯手术组 ;bax的表达阳性率在单纯手术组和TACE组无显著性差异 (Ρ >0 .0 5 )。结论　TACE治疗可以促进肝癌细胞fas表达增高 ,使bcl -xl表达降低 ,从而在总体上增加肝癌细胞凋亡率 ,促使肿瘤缩小。关于TACE治疗对bax的影响有待进一步研究     

Pharmacokinetics of peptide T in patients with Acquired Immunodeficiency Syndrome (AIDS)

1. The pharmacokinetics of Dalal-peptide T-NH2 (peptide T) was determined during phase I clinical trials in patients with acquired immunodeficiecy disease (AIDS) and AIDS related complex (ARC). Drug levels were determined by specific RIA, and in some cases with HPLC analysis, after intraveneous (i.v.) or intranasal (i.n.), via metered sprayer, administration.

2. The plasma kinetics appeared to be bi-phasic with a first compartment half-life of 30 to 60 minutes and a second plasma clearence rate of 4 to 6 hours, observed for both routes of administration. Peptide T, in one individual was confirmed to be present at 6 hrs in plasma, determined after HPLC isolation followed by specific RIA.

3. Bioavailabilty, determined for a 2 mg test dose in six individuals was 9.3 ± 6.9 nmol/L. Peak plasma levels of 41 ± 30 nmol/L after 10 mg i.n., 2.8 ± 5.9 nmol/L after 2mg i.n., and 0.13 ± 0.07 nmol/L after 0.4 mg i.n. were observed. In two individuals tested, peptide T was detected in CSF at levels 20% of the corresponding plasma level 90 and 145 minutes post i.v. administration. Peptide T was not detected in urine. I.N. administration was well tolerated for times up to 21 months.     

产程中应用杜冷丁对产程及新生儿的影响

目的　观察杜冷丁对产程及新生儿的影响。方法　将 16 0例初产妇随机分为观察组和对照组 ,各 80例 ,观察组在宫口开大 1.2cm时杜冷丁 10 0mg肌肉注射 ,对照组未用药。结果　第一产程用药组与对照组相比明显缩短 ,有显著差异 (P <0 .0 5 ) ,第二、三产程无差异 (P >0 .0 5 ) ,对新生儿影响、产后 2小时内出血量及新生儿体重两组无差异 (P >0 .0 5 )。结论　产程中应用杜冷丁可减轻产妇疼痛 ,缩短第一产程 ,不增加新生儿窒息 ,值得推广应用